Slotervaart Medical Centre, 9D
135 articles with Agendia, Inc.
Agendia and Paige Announce Landmark Strategic Partnership to Revolutionize Treatment Planning in Breast Cancer
Co-development program will utilize next-generation digital pathology platform and AI-based technology to provide real-time genomic testing results
Agendia to Showcase Robust Clinical Research at SABCS 2020 Emphasizing Need for Diversity of Data to Treat Breast Cancer Patients
Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that it will present new data from ongoing clinical research evaluating the MammaPrint ® and BluePrint ® genomic tests at the upcoming 2020 San Antonio Breast Cancer
Agendia Presents Robust and Accurate Next Generation Sequencing Results at the Association for Molecular Pathology 2020 Annual Meeting & Expo
Agendia, Inc., a world leader in precision oncology for breast cancer, today announced a poster presentation at the Association for Molecular Pathology (AMP) 2020 Annual Meeting & Expo.
Agendia, Inc., a world leader in precision oncology for breast cancer, today announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference, which takes place November 30 – December 3, 2020.
Agendia, Inc ., a world leader in precision oncology for breast cancer, today announced its participation in the 2020 Canaccord Genuity Virtual MedTech & Diagnostics Forum, which takes place November 19, 2020 . Agendia Chief Executive Mark Straley will present on Thursday, November 19 at 9:00 am ET , and will be accompan
Laura van 't Veer among 15 trailblazers in oncology honored at the 2020 virtual awards ceremony
Agendia Inc., a world leader in precision oncology for breast cancer, announced that the Federal Joint Committee has approved MammaPrint®, Agendia's 70-Gene Breast Cancer Recurrence Assay.
Agendia, HiSS Diagnostics and PathoNext offer local MammaPrint and BluePrint testing for breast cancer patients in Germany
Agendia Inc., a world leader in precision oncology for breast cancer, announced the availability of local testing for its CE-marked MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping tests, provided by PathoNext lab in Leipzig, Germany.
Agendia Presents New Data Demonstrating Clinical Utility for MammaPrint and BluePrint at the 2020 European Breast Cancer Conference Virtual Event
Presentations to include follow-up MINDACT study data and evaluations on the use of MammaPrint to guide treatment decisions in lobular cancers and for screen-detected breast cancers versus interval-detected breast cancers IRVINE, Calif. , Oct. 2, 2020 /PRNewswire/ -- Agendia, Inc., a world leader in precision oncology for breast cancer, today announced the presentation o
In celebration of Breast Cancer Awareness Month, Agendia, Inc ., a world leader in precision oncology for breast cancer, is proud to present the I AM HERE campaign, a collection of illustrations and stories that capture the incredibly personal journey of a breast canc
Agendia Presents New Data Demonstrating MammaPrint's Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients at the European Society for Medical Oncology Virtual Congress
Agendia, Inc., a world leader in precision oncology for breast cancer, presented data at the European Society for Medical Oncology Virtual Congress 2020 showing that MammaPrint's Ultra-Low risk threshold can identify postmenopausal breast cancer patients who will have an excellent prognosis with limited or no tamoxifen treatment.
Use of MammaPrint genetic assay alongside clinical assessment is cost-effective versus clinical assessment alone
Agendia Expands Management Team to Meet Company Momentum, Appoints Brian Dow as Chief Financial Officer
Chief Operating Officer Kurt Becker to Take on Broadened Role Overseeing Global Operations and Research and Development
Agendia Publishes Unprecedented Full Genome Dataset from MINDACT Trial for the Advancement of Translational Research in Communications Biology
Agendia, Inc., a world leader in precision oncology for breast cancer, announced the publication of MINDACT trial data in the July 27 issue of Communications Biology, a Nature Publishers Journal.
Long-Term Follow Up Data from Groundbreaking MINDACT Study Continues to Demonstrate Clinical Utility of MammaPrint™
Agendia, Inc., a world leader in precision oncology for breast cancer, announced new data from MINDACT, the prospective randomized trial designed to further demonstrate the clinical utility of MammaPrint® risk scoring when determining a breast cancer patient's need for chemotherapy.
Agendia Announces Data Presented at ASCO 2020 Demonstrating Importance of Further Classification of Breast Cancers to Enable Precise Prognosis and Treatment
Presentations outline how BluePrint® genomic testing enables further categorization of HER2-positive cancer and reclassification of ER+ tumors for patients' benefit FLEX registry reinforces the clinical and real-world utility of MammaPrint® and BluePrint to improve stratification of breast cancer patients [29-May-2020] IRVINE, Calif. and AMSTERDAM , May 29,
Agendia to Showcase New Data at ASCO 2020 That Further Stratifies Breast Cancer Patients for More Precise Therapy Recommendations
Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that they will present new data from its ongoing clinical research evaluating the MammaPrint® and BluePrint® genomic tests at the upcoming American Society of Clinical Oncology Annual Meeting (ASCO), taking place virtually May 29-May 31, 2020.
Agendia Co-Founder and Chief Scientific Officer René Bernards, PhD Elected to the National Academy of Sciences
Development of MammaPrint®, first FDA-cleared molecular diagnostic test for personalized treatment of breast cancer, considered a landmark achievement in breast cancer testing and treatment
Agendia, Inc., a world leader in precision oncology, announced today the appointment of industry veterans Laurie Heilmann and François Ferré, Ph.D. to its board of directors.
Simultaneous creation of Global Lab Center of Excellence